-

BiomX to Report Second Quarter 2020 Financial Results on Aug. 13, 2020

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE: PHGE), a clinical-stage company developing both natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and live audio webcast on Thursday, Aug. 13, 2020, at 8:00 a.m. EDT, to report second quarter 2020 financial results and provide a corporate update. The conference call dial-in numbers are 1-877-407-0724 (U.S.), 1-809-406-247 (Israel) or 1-201-389-0898 (international). The live and archived webcast will be available in the Investors section of the company’s website at www.biomx.com.

About BiomX

BiomX is a clinical-stage biotechnology company developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC), and colorectal cancer (CRC). BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets. For additional information, please see www.biomx.com.

Contacts

Noel Kurdi, BiomX
VP, Investor Relations and Strategy
(646) 241-4400
noelk@biomx.com

Media contact:
Rich Allan, Solebury Trout
(646)-378-2958
rallan@soleburytrout.com

Industry:

BiomX Inc.

NYSEAM:PHGE
Release Versions
English

Contacts

Noel Kurdi, BiomX
VP, Investor Relations and Strategy
(646) 241-4400
noelk@biomx.com

Media contact:
Rich Allan, Solebury Trout
(646)-378-2958
rallan@soleburytrout.com

More News From BiomX Inc.

BiomX Presents Preclinical Results With BX005 for Atopic Dermatitis at the Revolutionizing Atopic Dermatitis 2021 Virtual Conference and the International Conference on Phage Therapy and Bacteriophages

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that preclinical results with BX005 in atopic dermatitis were presented at the Revolutionizing Atopic Dermatitis (“RAD”) 2021 Virtual Conference and will also be presented at the upcoming International Conference on Phage Therapy and Bacteriophages. RA...

BiomX to Present Preclinical Results with BX004 in Cystic Fibrosis at the 44th European Cystic Fibrosis Conference

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that preclinical results with BX004 in Cystic Fibrosis (“CF”) will be presented at the 44th European Cystic Fibrosis Conference (“ECFS”). ECFS will be held from June 9-12, 2021. “Our upcoming presentation at ECFS highlights the capability of our BOLT p...

BiomX Reports First Quarter 2021 Financial Results and Provides Business Updates

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results and provided business updates for the first quarter ended March 31, 2021. “We are off to a strong start in 2021 and are well-positioned to continue making solid progress throughout our entire pipeline of novel phage therapies with the...
Back to Newsroom